# Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

> **NCT01921790** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma, Nasal Type

## Interventions

- **BIOLOGICAL:** Avastin
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Pegaspargase
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01921790
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-08
- **Primary completion:** 2015-08
- **Final completion:** 2020-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-08-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01921790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01921790, "Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01921790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*